Every S-1 that Inspire Veterinary Partners, Inc. (IVP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow IVP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVP filings page.
Inspire Veterinary Partners, Inc. is registering up to 200,000,000 shares of Class A common stock for resale by a single selling stockholder under a secured convertible notes financing. The shares include stock issued and issuable from a $975,000 First Note, a Second Note of up to $650,000, and related equity consideration.
The company will not receive any proceeds from the selling stockholder’s resale of these shares. As of this prospectus, 118,953,260 shares were outstanding, with a maximum of 318,953,260 shares outstanding if all registered shares are issued. Inspire Veterinary operates 14 veterinary hospitals across nine states and recently increased its authorized common stock to 700,000,000 shares.
The filing highlights recent challenges, including a Nasdaq delisting for failure to meet the minimum bid price, with trading moved to the OTCQB under the symbol “IVPR,” and substantial net losses of $14.3 million in 2024 and $14.8 million in 2023. Management and auditors express substantial doubt about the company’s ability to continue as a going concern given limited cash of $723,690 as of December 31, 2024 and the need to raise additional capital.
Inspire Veterinary Partners, Inc. has filed an S-1 to register up to 200,000,000 shares of Class A common stock for potential resale by a single selling stockholder, mainly tied to two secured convertible promissory notes and related share consideration. The company will not receive proceeds from any resale of these shares. If all securities are issued and converted, shares outstanding could rise from 118,953,260 to 318,953,260.
The business owns 14 small-animal veterinary hospitals across nine U.S. states and aims to grow through acquisitions. It remains unprofitable, with a 2024 net loss of $14,264,261, an accumulated deficit of $36,350,281 and cash and restricted cash of $723,690 as of December 31, 2024, leading auditors to highlight substantial doubt about its ability to continue as a going concern.
The company has received a Nasdaq delisting notice for failure to meet the minimum bid price, with a hearing held on January 13, 2026 and the outcome pending. Recent actions include increasing authorized common shares to 700,000,000, issuing stock to cancel portions of a prior note, and granting 9,450,000 shares under a consulting agreement, all of which add to potential dilution and highlight its reliance on equity-linked financing.
Inspire Veterinary Partners, Inc. (IVP) is filing an S-1 that describes a roll-up veterinary business model driven by acquisitions of individual hospitals and related real estate. For the six months ended June 30, 2025, the company reported $16.59M of revenue (flat year-over-year) and a net loss of $5.45M, and it sustained a net loss of $3.03M for the three months ended June 30, 2025. Management discloses substantial acquisitions completed since 2021 (multiple clinics with transaction values reported) and ongoing financing from notes, convertible instruments, a common stock purchase agreement and other debt.
The filing discloses notes payable of approximately $11.98M, elevated interest expense and non-cash charges that contributed to a going-concern statement: management says additional financing is required to continue operations for the next 12 months. The prospectus also notes a Nasdaq listing deficiency and potential dilution from a range of outstanding warrants, options and preferred conversions totaling material share counts.
Inspire Veterinary Partners, Inc. (IVP) filed an S-1 registration statement describing an offering of Class A common stock and related resale registration rights with investor Seven Knots, LLC. The company discloses it has a limited operating history, is not profitable, and has generated U.S. net operating loss carryforwards that may be unusable if future taxable income does not materialize. IVP lists numerous operational and regulatory risks including challenges integrating acquisitions, recruiting and retaining veterinarians, cybersecurity and data risks, compliance with state and federal veterinary and controlled-substance laws, and Nasdaq listing deficiency notices. The prospectus summarizes outstanding and potentially issuable equity: 3,609,285 Class A shares outstanding as of September 16, 2025; multiple tranches of warrants, options and convertible preferred stock that together could materially increase diluted shares (examples include 7,593,000 shares from conversion of Series B preferred, 1,092,896+1,092,896 warrants at $1.83, and 9,450,000 shares reserved under the 2022 Equity Incentive Plan). The offering contemplates up to 35,000,000 Class A shares in this offering on a pro forma as-adjusted basis and describes conditions required for purchase agreement effectiveness.